Evidence map›Paper›PMID 40465128›Full record

ReviewInternational journal of clinical oncology2025

Guidance on the short hydration method for cisplatin administration.

Kiichiro Ninomiya, Kei Kunimasa, Yasuko Kurata, Yuki Sato, Yasuhito Fujisaka, Hitoshi Ishikawa, Katsuyuki Hotta

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kiichiro NinomiyaCenter for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
Kei KunimasaDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Yasuko KurataDepartment of Pharmacy, Okayama University Hospital, Okayama, Japan.
Yuki SatoDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Yasuhito FujisakaDepartment of Medical Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Hitoshi IshikawaQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Katsuyuki HottaCenter for Innovative Clinical Medicine, Okayama University Hospital, 2-5-1, Shikata-Cho, Okayama, 700-8558, Japan. khotta@okayama-u.ac.jp.ORCID http://orcid.org/0000-0002-0112-0843

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin is currently used as the central agent in several cancer chemotherapy protocols because of its broad antitumor spectrum and potent antitumor effects; however, preventing cisplatin-induced renal damage and other adverse events is challenging. Recently, several clinical studies have shown that a short hydration method could prevent cisplatin-induced renal damage. In addition, appropriate magnesium supplementation and administration of forced diuretics have been shown to be renoprotective. The Japanese Lung Cancer Society Guidelines Committee has summarized the evidence of renal protection regarding cisplatin administration to provide optimal administration guidance for the cisplatin short hydration method.

Indexed as

Antineoplastic AgentsCisplatinFluid TherapyNeoplasmsHumansMagnesiumPractice Guidelines as TopicAntineoplastic AgentsCisplatinMagnesiumCisplatinForced diureticsMagnesium supplementationShort hydration

Identifiers

PMID40465128
PMCPMC12187873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.